Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Handelsbanken Fonder changes auditor

Today's Annual General Meeting in Handelsbanken Fonder AB appointed PricewaterhouseCoopers (PwC) as auditor for the Management Company, with the authorized public accountant Helena Kaiser de Carolis as auditor in charge. PwC will also be the auditor for the mutual funds managed by the Management Company, including its exchange-traded funds and Helena Kaiser de Carolis will also serve as the auditor in charge for the Management Company’s mutual funds. PwC will replace Ernst & Young (auditor in charge, Jesper Nilsson) as the auditing firm.  For further information, please contact:

Esmaeilzadeh Holding AB publishes report for the first quarter 2022

“During the first quarter, EHAB strengthened its cash position with a bond loan of SEK 1.2 billion and is therefore in a very good position to finance the high level of activity in our portfolio. At the same time, EHAB continues to pursue its strategic and long-term initiatives to achieve economies of scale and to streamline and consolidate the portfolio, which we believe will benefit both investors and our portfolio companies.” - Saeid Esmaeilzadeh, CEO Financial overview · Total net asset value was SEK 4,374 million (SEK 277 million), equivalent to SEK 5,770 per share (SEK 1,107)

Lytix Biopharma AS announces that an abstract on LTX-315 in combination with Adoptive Cell Therapy is selected for a poster presentation at ASCO 2022

Oslo, Norway, May 27, 2022 – Lytix Biopharma AS (“Lytix” or the “Company”), a clinical-stage company with an in situ vaccination technology platform, announces that an abstract relating to LTX-315 in combination with Adoptive Cell Therapy (ACT) has been selected for presentation at a Poster Session during American Society of Clinical Oncology (ASCO) 2022. LTX-315 is a first-in-class oncolytic molecule, representing a new and superior in situ therapeutic vaccination principle to boost the clonal expansion of T cells and subsequent anti-cancer immunity.Immune- and clinical response data from

Lantmännen moves shares from HaGe Nord AG to team SE

Lantmännen converts its shares in Hauptgenossenschaft Nord AG ("HaGE") into newly issued shares in team SE, a company in Germany with operations within construction trade and energy ("Team").  The Danish cooperative DLG is the majority shareholder in both HaGe and Team and the transaction is being made against the background of a restructuring within the DLG portfolio.DLG will convert most of its shares in HaGe into newly issued shares in Team and thus become an approximately 70 percent owner in Team.  Lantmännen, which owns about 41 percent of HaGe, will after the transaction own about 10.

Read original

Baseload Capital Sweden AB (publ) today releases the results for the period 1 January – 31 March 2022

Interim report for the period 1 January – 31 March 2022 During the first quarter, we have initiated a written procedure with regards to our green bond to ensure the opportunity to redeem our bond at par and started planning for a series B round in the company to finance the upcoming growth phase. · The result for the first quarter was SEK -30.5 million. Revaluation of projects and loans to subsidiaries accounted for SEK -17.4 million, of which SEK -5.9 million consisted of exchange rate differences as a result of a stronger Swedish krona. · In Iceland, the focus during

Panoro Energy: Grant of Share Options

Mandatory notification of TradesOslo, 27 May 2022 – Following the approval by the Ordinary General Meeting (“2022 AGM”) of Panoro Energy ASA (“Panoro” or the “Company” with OSE Ticker: PEN) held on 25 May 2022, the Company announces an award of 24,000 options (“Board Options”) granted to the Ms Grace Skaugen which will vest equally over a three-year period each at the date of the Annual General Meetings of upcoming years. Each Board Option entitles the holder to one ordinary share in the Company. Once vested, the options are exercisable at NOK 31.91 per share. The exercise price, as per the

Hunter Group ASA - First quarter results 2022

Total revenues of USD 7.63m - Spot pool revenues of USD 1.33m - Time charter revenues of USD 6.44m Total operating expenses of USD 6.72m - Vessel opex incl. insurance of USD 2.51m - Voyage exp. and commissions of USD 0.48m - G&A expenses of USD 0.53m     - USD 0.29m administrative expenses     - USD 0.28m legal expenses EBITDA of USD 4.24m Net profit of USD -0.70m Average daily earnings of USD 21,565 - Avg. daily spot earnings of USD 14,720 - Avg. daily time charter earnings of USD 23,850 Opex incl. insurance of USD 6,975 per day per vessel 360

Crunchfish opens a subsidiary in India. No. 1 real-time payments market in the world.

Crunchfish Digital Cash AB expands its operation with the recently opened subsidiary Crunchfish India Private Limited Company. Digital payments is growing very fast in India and is likely to surpass 100 billion transactions already in 2022 and projected to go beyond 500 billion in 2025. The Crunchfish India subsidiary will be strengthen Crunchfish’s market presence in India and demonstrate its commitment to the market.Crunchfish takes further steps in its establishment in India through the newly registered Crunchfish India Private Limited Company. The Indian subsidiary provides the enabling

Change in Oriola Management Team: Sari Pohjonen to leave Oriola

Oriola Corporation Stock Exchange Release 27 May 2022 at 8:30 a.m. Change in Oriola Management Team: Sari Pohjonen to leave Oriola Sari Pohjonen, the CFO of Oriola Corporation, has resigned and will focus on board and advisory roles. She will leave Oriola by the end of September 2022. “I want to express my thanks to Sari Pohjonen for her time at Oriola. We will continue to work closely with her in the coming months to advance our turnaround actions and the planned pharmacy joint venture in Sweden. At Oriola, our focus is to ensure successful turnaround actions, consisting of four

SAY Seltzer design wins the Dieline award

Since 2020, the drinks industry has been buzzing about hard seltzers. In the Nordics, the category was not yet fully formed and the name ‘seltzer’ sounded vague to consumers, when Anora introduced this fast-growing segment in Finland as one of the first players in the market.The first SAY Seltzers  were launched for the spring selection in 2021, when SAY Seltzer Strawberry & Raspberry 4% and SAY Seltzer Orange & Guarana 4% were introduced to consumers. For summer 2022, SAY Seltzer introduced two new flavors, Grapefruit &

Realfiction Holding AB announces its Q1 Interim Report for January – March 2022

Realfiction Holding AB (“Realfiction” or the “Company”) announces that the Q1 Interim Report for January – March 2022 is now available. The full report is attached as a separate document and can also be downloaded from the Company’s website (www.realfiction.com). A printed copy can be ordered via investor@realfiction.com. Below is a brief summary of the Q1 Interim Report.Important key figures:• 91% increase in total revenue Q1, 2022 compared to Q1, 2021• 139% increase in gross profit in Q1, 2022 compared to Q1, 2021• 24.9% increase (12.9 points) in gross profit margin in Q1, 2022

Ponsse’s new products for responsible forestry

Ponsse launches excellent new products to improve productivity in sustainable harvesting. The new solutions have been developed together with customers, listening to their needs. The PONSSE Scorpion Giant harvester and the PONSSE Mammoth forwarder respond to the highest requirements of modern forestry both in terms of ergonomics and productivity.   “These new products strengthen our position as one of the world’s leading suppliers of responsible harvesting solutions. The development of both new forest machines started from improved ergonomics, safety and usability, as well as better

Targovax announces publication of the two abstracts accepted for poster presentation at ASCO 2022

· The first poster summarizes the complete efficacy and immunological study data for the Targovax-sponsored mesothelioma trial, showing strong 30-month survival rate of 34.3% in the ONCOS-102-treated group vs. 18.2% in the control group · The second poster presents clinical data from the externally sponsored trial exploring intra-peritoneal (IP) delivery in colorectal or ovarian cancer with peritoneal metastasis, showing that ONCOS-102 generated immune responses and was safe to administer IP in combination with a PD-L1 checkpoint inhibitor Oslo, Norway, 27 May 2022 – Targovax ASA (OSE:

Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new results from the phase Ib clinical trial CIRIFOUR in 15 solid tumor patients, no longer responding to PD-(L)1 inhibitor therapy, treated with nadunolimab (CAN04) as an add-on to Keytruda® (pembrolizumab). The results are positive, with favorable safety. Disease control for at least 30 weeks was also achieved by the combination in a patient subgroup, identified by lower levels of the biomarkers CRP and IL-6 and higher levels of immune cells in the tumor tissue at baseline. These results will be presented at the ASCO 2022

Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported extended interim results in first-line pancreatic cancer (PDAC) patients treated with nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in the phase I/IIa CANFOUR trial. The efficacy was superior to historical data for chemotherapy only. In the 73 patients evaluable, median overall survival (OS) was 12.7 months with 1-year survival of 57% and median progression-free survival (iPFS) of 7.2 months. The safety profile was acceptable and in line with the earlier data set. These data strengthen previous positive

Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported updated interim results for non-small cell lung cancer (NSCLC) patients treated with nadunolimab (CAN04) in combination with gemcitabine and cisplatin, showing efficacy well above historical controls. With 30 patients evaluable, overall response rate (ORR) was 53%, disease control rate 83%, median progression-free survival (PFS) 6.8 months and median overall survival (OS) 13.7 months. The strongest efficacy benefits were seen in patients with non-squamous NSCLC, particularly those treated previously with a checkpoint inhibitor.

Investor Report

Regulatory Announcement Royal Bank of CanadaMay 26, 2022 RBC Covered Bond Programme Monthly Investor Report The RBC Covered Bond Programme Monthly Investor Report has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism To view the full document, please paste the following URL into the address bar of your browser. RBC Covered Bond Programme Monthly Investor Report dated April 29, 2022 http://www.rns-pdf.londonstockexchange.com/rns/9944M_1-2022-5-26.pdf A copy of the RBC

2nd Quarter Results

Regulatory Announcement Royal Bank of Canada May 26, 2022 Second Quarter 2022 Report to Shareholders The Second Quarter 2022 Report to Shareholders has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism To view the full document, please paste the following URL into the address bar of your browser. Second Quarter 2022 Report to Shareholders dated May 26, 2022 http://www.rns-pdf.londonstockexchange.com/rns/  A

2nd Quarter Results

Regulatory Announcement Second Quarter 2022 Earnings Release The Second Quarter 2022 Earnings Release has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism To view the full document, please paste the following URL into the address bar of your browser. Second Quarter 2022 Earnings Release dated May 26, 2022 http://www.rns-pdf.londonstockexchange.com/rns/9822M_1-2022-5-26.pdf A copy of the Second Quarter 2022 Earnings Release may also be viewed at www.rbc.com. For

Enauta’s FPSO Atlanta to be Operated to ABS Class

ABS Maintains FPSO Class Leadership in Brazil(DUBAI) The FPSO Atlanta, contracted by Enauta to Yinson for conversion to service the Atlanta Field offshore Brazil, will be operated under ABS Class. The Atlanta, which is being converted in Dubai Drydocks World, including structural upgrades, refurbishment and enhancement of equipment, will have a production capacity of 50,000 BOPD, 12.4 MMscfd gas and a storage capacity of 1,800,000 bbl. Operated by Enauta, the Atlanta Field is located in the Santos Basin, block BS-4, at 1,500 m water depth with estimated reserves of 106 MMbbl. Formerly

Realheart and KTH Receive SEK 4 Million Grant from Vinnova

Press release 26 May, 2022 Realheart and KTH have received a grant of SEK 4 million from Vinnova to jointly develop a Swedish hybrid simulator that will enable advanced testing of algorithms that control Realheart's artificial heart, but also will contribute to increasing Sweden's overall competitiveness in cardiovascular device innovation.A hybrid simulator consists of digital model of the human heart, lungs, and blood vessels, to which an artificial heart, for example, can be physically connected to study how the device interacts with the body. Similar methodology was used in the

Scandinavian ChemoTech’s TSE technology gives hope to horses suffering from sarcoids

Today the ESVONC congress in Syracuse, Italy, opens. In a poster, presented at the congress, the Tumour Specific Electroporation - TSE™ treatment of a horse is outlined and described as showing outstanding results.The author of this poster is DVM (Doctor in Veterinary Medicine) Majbritt M E Larsen, Specialist in small animal internal medicine and head of Oncology at Evidensia Specialistdjursjukhuset Helsingborg. The title of the poster is: “Treatment of equine sarcoids using intratumoral Bleomycin in combination with Tumour Specific Electroporation - TSE™” and describes the outstanding

There are no items matching the current filter
There are no more items matching the current filter
Back to top